Xenon Pharmaceuticals
XENE
17 hedge funds and large institutions have $83.1M invested in Xenon Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 17 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
30.06% more ownership
Funds ownership: 0% → 30.06% (+30%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.4M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$9.7M |
| 3 |
BVF Inc
San Francisco,
California
|
+$9.08M |
| 4 |
Visium Asset Management
New York
|
+$6.61M |
| 5 |
Invesco Private Capital
New York
|
+$6.53M |
Top Sellers
XENE Hedge Fund Activity: Q4 2014 in Review
17 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2014, worth a combined $83.1M.
Buyers outnumbered sellers: 17 funds opened new XENE positions and 0 closed out — a net gain of 17 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $18.4M.
- 17 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $83.1M of Xenon Pharmaceuticals stock for Q4 2014.
- 17 funds opened new Xenon Pharmaceuticals positions in Q4 2014 and 0 closed out, a net change of +17 holders.
- The largest Xenon Pharmaceuticals buyer in Q4 2014 was Fidelity Investments, an estimated $18.4M added.
Based on aggregated 13F filings for Q4 2014.